Drug Profile
Head and neck cancer DNA vaccine - Immune Cell Therapy
Alternative Names: IC-1002; IC-1002 personalised head and neck cancer vaccine; IC-1002 personalized head and neck cancer vaccineLatest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator Immune Cell Therapy
- Class Cancer vaccines; DNA vaccines; Gene therapies
- Mechanism of Action Gene transference; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Head and neck cancer
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Head and neck cancer in USA (Intradermal)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Head-and-neck-cancer in USA (Intradermal, Injection)
- 19 Sep 2017 Immune Cell Therapy and the University of Pittsburgh withdrawn a phase I trial for Head and neck cancer in USA prior to enrolment, before September 2017 (NCT02211027)